How to Trip Rapid Review
Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)
Step 2: press
Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.
- 35 results
- Evidence type
- Clinical Area
Use check boxes to select individual results below
SmartSearch available
Trip's SmartSearch engine has discovered connected searches & results. Click to show1. Overdiagnosis of Thyroid Cancer in the Marne and Ardennes Departments of France From 1975 to 2014
Overdiagnosis of Thyroid Cancer in the Marne and Ardennes Departments of France From 1975 to 2014 Overdiagnosis of Thyroid Cancer in the Marne and Ardennes Departments of France From 1975 to 2014 - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove (...) one or more studies before adding more. Overdiagnosis of Thyroid Cancer in the Marne and Ardennes Departments of France From 1975 to 2014 (OTCancer) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03623516 Recruitment Status : Completed First Posted : August 9, 2018 Last Update Posted : August 9
2018 Clinical Trials
2. Time Trend Analysis of PE Diagnosis With SPECT V/Q: a Single Institution Observational Study
. The hypothesis was that the use of SPECT V/Q may be responsible for an overdiagnosis of PE, especially at the implementation phase of the test. The aim of this study was to perform a time trend analysis of the evolution over the years of PE diagnosis with SPECT V/Q. Condition or disease Pulmonary Embolism Study Design Go to Layout table for study information Study Type : Observational Actual Enrollment : 2000 participants Observational Model: Cohort Time Perspective: Retrospective Official Title: Time Trend
2018 Clinical Trials
3. Ideas, Concerns, Expectations. Implementing Patient-centered Communication
Collaborators: German Federal Ministry of Education and Research University of Erlangen-Nürnberg Information provided by (Responsible Party): University of Erlangen-Nürnberg Medical School Study Details Study Description Go to Brief Summary: Exploring patients` ideas, concerns and expectation (ICE) is a communication tool to promote patient centredness and shared decision making during a consultation. This study evaluates whether offering ICE training to doctors can decrease overdiagnosis in the management (...) of acute backache. Condition or disease Intervention/treatment Phase Communication Back Pain Other: Workshop "ICE training" Not Applicable Detailed Description: The study is a cluster randomized trial recruiting general practitioner from practices in Northern Bavaria/Germany forming a research network within the recently implemented framework of PRO PRICARE (Preventing Overdiagnosis in Primary Care). At baseline, the intervention group (24 out of 48 doctors) will take part in a one-day training session
2018 Clinical Trials
4. Discussing Stopping Cancer Screening and Prognosis With Older Adults
chance of experiencing the life prolonging benefits of cancer screening and instead may only experience harm from being screened. The most concerning harm of cancer screening is overdiagnosis - the diagnosis and treatment of cancers that otherwise would not have caused problems in an older adult's lifetime. Despite this, around half of adults >75 years with <10 year life expectancy are regularly screened for cancer. One reason for the overuse of these tests is that PCPs feel uncomfortable discussing
2018 Clinical Trials
5. Harms of Hepatocellular Carcinoma Surveillance
a multi-center randomized controlled trial assessing screening benefits in a socioeconomically and racially diverse population of 3,000 patients with cirrhosis followed in 3 healthcare settings over a 4-year period, this study aims to: Aim 1: Assess the effect of hepatocellular carcinoma screening on a) physical harms due to follow-up tests, b) financial harms, and c) overdiagnosis in patients with severe liver dysfunction or comorbid illness, through electronic medical record data, manual chart (...) of costs per person. Degree of financial harms will be compared between the hepatocellular carcinoma screening and usual care arms using Student T test, with a secondary analysis stratified by health system. In a secondary analysis, a mixed-effect model approach will be employed to identify patient-, provider- and system-level factors associated with financial harm. Overdiagnosis [ Time Frame: 4 Years ] Defined as hepatocellular carcinoma diagnoses that are unlikely to have an effect on mortality
2018 Clinical Trials
6. Upper Limit for TSH of First and Second Trimester Pregnancy in Turkey
Sponsor: Bartin State Hospital Information provided by (Responsible Party): Murat Yassa, Bartin State Hospital Study Details Study Description Go to Brief Summary: Physiological changes necessitate the use of pregnancy-specific reference ranges for TSH and FT4 to diagnose thyroid dysfunction during pregnancy. Although many centers use fixed upper limits for TSH of 2.5 or 3.0 mU/L, this may lead to overdiagnosis or even overtreatment. The new guidelines of the American Thyroid Association have
2018 Clinical Trials
7. A Randomized Trial of Early Detection of Clinically Significant Prostate Cancer (ProScreen)
-based randomised trial of prostate cancer screening will be carried out. A total of approximately 67,000 men aged 50-63 in Helsinki and Tampere are randomised to intervention (screening) or control arm. A reduction in harms of screening in the form of overdiagnosis is sought, while retaining as much as possible of the mortality benefit (reduction in prostate cancer mortality). Novel methods that have been shown to increase specificity for clinically relevant prostate cancer but never tested (...) . The project introduces a novel concept for PC screening that minimises overdiagnosis and overtreatment, while retaining the mortality benefit to shift the balance of screening benefits and harms to a favourable net effect. The strategy for implementation as a randomised screening trial utilises three levels of risk assessment (PSA, kallikrein panel and MRI) before the diagnostic procedure (prostate biopsy), each aimed at eliminating detection of indolent disease. The study hypothesis is that by virtue
2018 Clinical Trials
8. Early and Accurate Detection of Prostate Cancer in General Practice
accurate diagnostic approach that can ensure early detection of aggressive PC while curable, reduce unnecessary prostate biopsies incl. risk of sepsis and reduce overdiagnosis/-treatment of indolent PC. New molecular biomarkers applied in general practice, serving as a pre-selection test for follow-up, and accurate and patient-friendly MR-imaging and MR-targeted biopsy at the hospital may help to solve these problems. In this study the investigators will assess the clinical utility of combining genetic
2017 Clinical Trials
9. Breast Cancer Screening: Digital Breast Tomosynthesis Versus Digital 2D Mammography
. Furthermore, the incidence rate of interval cancers within a 24 months interval after screening will be compared between both study arms in order to investigate the potential for overdiagnosis. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 80000 participants Allocation: Randomized Intervention Model: Parallel Assignment Intervention Model Description: Participants will be randomized to either Digital Breast Tomosynthesis plus
2017 Clinical Trials
10. Effect of Information About the Benefits and Harms of Mammography on Women's Decision Making
: September 14, 2017 Actual Study Completion Date : June 20, 2018 Resource links provided by the National Library of Medicine related topics: related topics: Arms and Interventions Go to Arm Intervention/treatment Experimental: Decision aid Women in the intervention arm will receive a leaflet with detailed information on the benefits (breast cancer mortality reduction, less intensive treatments) and harms (false positive results and overdiagnosis). Other: Decision aid for breast cancer screening Women (...) in the intervention arm will receive a leaflet with detailed information on the benefits (breast cancer mortality reduction, less intensive treatments) and harms (false positive results and overdiagnosis). Active Comparator: Control Women in the control arm will receive a standard leaflet that does not mention harms and recommends accepting the invitation to participate in the biennial exams of the EDBCP. Other: Standard leaflet Women in the control arm will receive a standard leaflet that does not mention harms
2017 Clinical Trials
11. Decision-aid on Breast Cancer Screening
Description: Breast cancer is the most common cancer in women. In Italy, women are invited to a population-based mammography screening programme for the first time at the age of 45 or 50 years. Results from randomised controlled trials, observational studies, and systematic reviews continuously fuel the debate on the balance on benefits (reducing breast cancer mortality) and harms (overdiagnosis, overtreatment) of mammography screening. Physicians, policy makers, as well as laypeople or patient (...) information and an aid for the decision to be taken. The content is splitted in 16-20 screens; each screen contains the answer to a common question (i.e. What is mammography screening? What are its benefits and harms? What results can be expected from the participation to mammography screening? What is breast cancer?). The information covers also controversial topics as overdiagnosis, overtreatment and the disagreement among scientists about harms and benefits' quantification. Active Comparator: Standard
2017 Clinical Trials
12. Aging Stereotypes and Prodromal Alzheimer's Disease
Impairment) can precede AD for 15 years. However, many individuals diagnosed with MCI do not convert to AD, some remaining stable and others even reversing back to normal (with rates of reversion to normal varying from 4.5% to as high as 53%). This over-diagnosis bias, which has been largely overlooked, is at the core of the present project at the interface of human and life sciences. Here, we argue that an important source of overdiagnosis in the prodromal state of AD comes from negative aging
2017 Clinical Trials
13. Intraoperative Radiation Therapy (IORT) in DCIS
and screening, the overdiagnosis and overtreatment of ductal carcinoma in situ (DCIS) have increased. Minimizing treatment toxicity and cost is a high priority area of research. Intraoperative Radiation Therapy (IORT)is a form of radiation where a single high dose of irradiation is applied to the tumor bed at the time of lumpectomy. Its use has not been previously studied in DCIS. Proposed advantages include decreased toxicity to adjacent tissue and organs, reduction in healthcare costs, and improved
2017 Clinical Trials
14. Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial For Low Risk DCIS
(AS) compared to guideline concordant care (GCC) in the setting of a pragmatic prospective randomized trial for low risk DCIS. Our overarching hypothesis is that management of low-risk Ductal Carcinoma in Situ (DCIS) using an AS approach does not yield inferior cancer or quality of life outcomes compared to GCC. Condition or disease Intervention/treatment Phase DCIS Ductal Carcinoma in Situ Other: Guideline Concordant Care Other: Active Surveillance Not Applicable Detailed Description: Overdiagnosis (...) and overtreatment resulting from mammographic screening have been estimated to be as high as 1 in 4 patients diagnosed with breast cancer although the absence of standard definitions for measuring overdiagnosis has led to much uncertainty around this estimate. The national health care expenditure resulting from false positive mammograms and breast cancer overdiagnosis has been estimated to approach $4 billion annually. There is general consensus that much of this burden derives from the treatment of DCIS
2016 Clinical Trials
15. Detection of High Grade Prostate Cancer With Subharmonic Ultrasound Imaging, A Pilot Study
that overdiagnosis and overtreatment of potentially insignificant cancer is a major drawback of prostate cancer screening, and point to the need for a more specific screening tool that can identify clinically significant prostate cancer. The US-based Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial failed to show a mortality benefit from screening and treatment of prostate cancer. The European Randomized Study of Screening for Prostate Cancer (ERSPC) suggests that with the current standard
2016 Clinical Trials
16. Lung Cancer Screening Decisions
for those with 30 pack years or more of smoking or who quit less than 15 years ago. Evidence clearly delineates both the benefits (mortality reduction) and harms (false positives, follow-up testing, risk of invasive testing, and risk of overdiagnosis) of lung cancer screening. Preliminary data from an HSR&D pilot grant finds that some Veterans are highly reluctant to enter the care pathway associated with lung cancer screening due to its potential harms. Additional preliminary data using Best Worst
2016 Clinical Trials
17. Seoul National University Prospectively Enrolled Registry for Prostate Cancer With Active Surveillance
surveillance as the primary endpoint of the current study. Condition or disease Intervention/treatment Prostate Cancer Procedure: Active surveillance Detailed Description: Prostate cancer (PCa) remains one of the most commonly diagnosed malignancies in men worldwide. Early diagnosis and definitive therapy seem to improve oncological outcomes in men with high-risk disease, but significant concerns exist in terms of the overdiagnosis and overtreatment of patients with lower-risk tumors. In this context
2016 Clinical Trials
18. Comparison of 3 Diagnostic Strategies of PE: Planar V/Q Scan, CTPA, and V/Q SPECT.
that a strategy based on V/Q SPECT could be an alternative to the two usual approaches responding rightly to the two mains issues and combining the advantages of CTPA (simplified diagnostic approach) and planar V/Q (no overdiagnosis, lower radiation exposure, no contraindication). Although a recent survey showed that up to 70% of nuclear medicine centers perform SPECT rather than planar imaging for diagnosing PE, a diagnostic management outcome study, in which diagnostic decision would be made on the basis
2016 Clinical Trials
19. Assessing Breast Density's Value in Imaging
Frame: From date of first screening examination until the date of death from any cause, up to 100 years of age ] Life-years gained estimated by the Cancer Intervention and Surveillance Modeling Network (CISNET) models Modeled Long-Term Mortality Outcome: Overdiagnosis (Aim 1) [ Time Frame: From date of first screening examination until the date of death from any cause, up to 100 years of age ] Overdiagnosis estimated by the Cancer Intervention and Surveillance Modeling Network (CISNET) models
2016 Clinical Trials
20. Screening for Breast Cancer With Digital Breast Tomosynthesis
occurring as interval cancers or at subsequent screens and allowing to estimate overdiagnosis. In Reggio Emilia a population-based screening program is active. It invites all women from 45 to 74 years old for a 2D digital mammography (2 projections, double reading) every 2 years (annually from 45 to 49). Women will be asked for informed consent when they attend the mammography. I they accept they will be randomised to one of the two arms. All examinations will be read by two independent radiologists
2016 Clinical Trials
Ongoing trials
Ongoing clinical trails via clinicaltrials.gov. In addition to ongoing trials it also includes completed trials as there is often a lag between a trial finishing and publication.